Otsuka’s Voyxact (anti-APRIL) moved the IgA nephropathy conversation again, with phase 3 eGFR-slope data suggesting the anti-APRIL monoclonal antibody could halt or reverse kidney function decline. The update adds momentum for a mechanism that targets APRIL biology to reduce downstream inflammatory and B-cell–linked drivers of disease. The reported dataset emphasizes renal functional trajectories rather than single timepoint endpoints, a framing that nephrology developers increasingly use for payer and guideline discussions. If the full program continues to support sustained kidney benefit, Voyxact could strengthen Otsuka’s position in a crowded immunology-driven nephrology pipeline. For clinicians, the key question is durability—whether the slope flattening translates into slower progression and better longer-term outcomes in subgroups defined by baseline disease status.